While it is known that the inflammatory state of the recipient may regulate the production of blood group antibodies, the cellular and molecular mechanisms are unclear. Mesenchymal stromal cells (MSCs) can produce inflammatory factors in response to inflammation and regulate inflammatory immunity. To explore how inflammatory MSCs exert influence on blood group antigen-antibody responses, the inflammatory MSC culture solution was added to the blood group antigen-antibody response system. Flow cytometry was used to detect the effect of different concentrations of inflammatory MSC supernatant on the production of blood group antibodies. Western blotting was used to determine whether the IL-1β receptor was expressed on the surface of red blood cells (RBCs). The intensity of antigen-antibody response was detected by serological methods. The results demonstrated that IL-1β produced by inflammation-induced MSCs could directly bind to the surface of erythrocytes and interfere with blood group antigen-antibody responses. This study suggests that inflammatory MSC-derived IL-1β might enhance the strength of blood antigen-antibody responses.

Objective To analyze the impact of sporadic cases of COVID-19 on the work of Transfusion Department, so as to explore the countermeasures. Methods The admission of inpatient departments, the reception of outpatient(including emergency) departments, the workload of transfusion department(including blood typing, unexpected antibody screening and cross matching), and the consumption of blood components in the Xijing Hospital between October and November in 2021, during COVID-19 outbreak, were collected. All the above data was statistically compared to the data in same period in 2018, before the COVID-19 outbreak. Results Due to the COVID-19 epidemic, there was a significant decrease in number of inpatients(280±157.1 vs 340.4±110.2), outpatient(including emergency)(8 359±3 615 vs 10 151±3 225), the workload of blood typing(272.0±132.4 vs 341.6±110.4), unexpected antibody screening(78.26±42.22 vs 98.51±43.53) and crossmatch(237.2±99 vs 475.7±155.6), as well as the consumption(U) of all blood components(457.9±50.32 vs 579.4±62.51) in the Xijing Hospital(P<0.05). In detail, the epidemic had the most direct impact on the number of inpatients and outpatients, which shrank continuously on the 2nd day after official announcement of the new COVID-1 cases. While the workload of blood typing, unexpected antibody screening and crossmatch decreased slightly, with a lag, usually on the 2nd, 3rd and 5th day after official announcement. The decrease of the usage of red blood cells and plasma began from the 7th day after the new epidemic to the 6th day after the end of the epidemic. However, the usage platelets and cryoprecipitate coagulation factors decreased from the 8th and 10th day after the new epidemic to the 2nd and 6th day after the end of the epidemic, respectively. Conclusion The daily work of Blood Transfusion Department has been seriously affected by sporadic COVID-19 epidemic. The working mode, staff structure and inventory ratio of blood components should be adjusted and optimized instantly to maintain the normal conduct of medical treatments in hospitals and ensure the safety of patients.

目的 分析亲体子宫移植患者围术期临床用血情况,探讨子宫移植患者围术期的输血策略,评估患者输血后疗效,初步制定我院关于子宫移植患者的输血方案,保障患者用血安全.方法 通过回顾性查阅临床病例资料,对我院2016年1月及2018年1月实施的2例亲体子宫移植患者术后血红蛋白急剧下降、凝血紊乱的原因及术后临床用血情况进行分析,复查输血相容性相关检查项目,红细胞均采用同型配合型输注治疗,非红血液制品均采用同型输注,观察移植前后患者血常规、凝血、血液生化等指标变化,并对子宫移植患者输血治疗有效性进行评估.结果 经分析,2例子宫移植患者围术期血常规、凝血指标变化明显系多方面因素所致,术后给予同型配合型辐照、去白细胞悬浮红细胞进行支持性治疗,结合多学科的临床救治,患者最终康复出院.结论 子宫移植患者围术期发生血红蛋白急剧下降、凝血紊乱的原因需考虑多方面因素,完善输血相关血清学检查的同时,应综合考虑患者的临床诊疗过程,给予正确的临床输血策略及临床治疗方案,保障患者安全.